Present status of modified hemoglobin as blood substitutes and oral therapy for end stage renal failure using artificial cells containing genetically engineered cells

Annals of the New York Academy of Sciences

Volumn 944, Issue , 2001, Pages 362-372

  Chang, Thomas Ming Swi ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Artificial cells; Blood substitutes; End state renal therapy; Genetically engineered cells; Modified hemoglobin; Oral therapy

Indexed keywords

BLOOD SUBSTITUTE; HEMOGLOBIN DERIVATIVE; POLYMERIZED HEMOGLOBIN; PYRIDOXYLPOLYHEMOGLOBIN;

ADULT; AGED; ARTIFICIAL MEMBRANE; BIOARTIFICIAL ORGAN; BLOOD SUBSTITUTION; CELL ENCAPSULATION; CHEMICAL MODIFICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GENETIC ENGINEERING; HEMOGLOBIN ANALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; KIDNEY FAILURE; MICROENCAPSULATION; PHASE 3 CLINICAL TRIAL;

EID: 0035687160     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03848.x     Document Type: Conference Paper

References (38)

1. Semipermeable microcapsules
2. Semipermeable aqueous microcapsules: I. Preparation and properties
3. Microencapsulated islets as bioartificial endocrine pancreas
4. Bioartificial organs II: Technology, medicine and material
5. Artificial cell biotechnology in medical applications
6. Red blood cell substitutes - Best practice & research
7. Stabilization of enzyme by microencapsulation with a concentrated protein solution or by crosslinking with glutaraldehyde
8. The clinical development of human polymerized hemoglobin
9. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery
10. Overview of preclinical and clinical efficacy of Biopure's HBOCs
11. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution
12. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia
13. T.M. Hemolink, an o-Raffinose crosslinked hemoglobin-based oxygen carrier
14. Blood and HemAssistTM (DCLHb): Potentially a complementary therapeutic team
15. Expression of fully functional tetrameric human hemoglobin in Escherichia coli
16. OptroTM (recombinant human hemoglobin): A therapeutic for the delivery of oxygen and the restoration of blood volume in the treatment of acute blood loss in trauma and surgery
17. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin
18. Nitric oxide scavengers in the treatment of shock associated with systemic inflammatory response syndrome
19. Polyhemoglobin-superoxide dismutase catalase as a blood substitute with antioxidant properties
20. Synthetic erythrocytes from lipid encapsulated hemoglobin
21. Polyethylene glyco-modified liposome-encapsulated hemoglobin: A long circulating red cell substitute
22. Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: Preparation and characterization
23. Nanoencapsulation of hemoglobin and rbc enzymes based on nanotechnology and biodegradable polymer
24. Therapeutic uses of microencapsulated genetically engineered cells
25. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats
26. Growth kinetics of genetically engineered E. coli DH5 cells in artificial cell apa membrane microcapsules: Preliminary report
27. Artificial cell microcapsules containing genetically engineered E. coli DH5 cells for in vitro lowering of plasma potassium, phosphate, magnesium, sodium, chloride, uric acid, cholesterol, and creatinine: A preliminary report
28. Live E. coli cells to treatment uremia: Replies to letters to the editor
29. Lowering of uric acid in vitro and in vivo by artificial cell microcapsulated genetically engineered E. coli DH 5 cells
30. Artificial cells microencapsulated genetically engineered E. coli DH5 cells for the lowering of plasma creatinine in vitro and in vivo
31. Growth and survival of renal failure rats that received oral microencapsulated genetically engineered E. coli DH5 cells for urea removal